Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TAU-2014-1: Phase I Trial of Mibefradil Dihydrochloride With Hypofractionated Re-Irradiation Therapy in Treating Patients With Recurrent Glioblastoma Multiforme (GBM)

NCT02202993 is registered in ClinicalTrials.gov with Cavion, Inc. as lead sponsor.

NCT NCT02202993
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02202993 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TAU-2014-1: Phase I Trial of Mibefradil Dihydrochloride With Hypofractionated Re-Irradiation Therapy in Treating Patients With Recurrent Glioblastoma Multiforme (GBM)
Lead sponsor
Cavion, Inc.
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2014
Completion date
September 29, 2017
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme (gbm)